Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn pyrrolidone carboxylic acid
learn DECAPEPTIDE-28
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 62 results
research Phospholipid–polymer hybrid nanoparticle-mediated transfollicular delivery of quercetin: prospective implement for the treatment of androgenic alopecia
Quercetin-loaded nanoparticles can penetrate skin, minimize hair loss, and promote hair regrowth, showing slightly better results than a marketed product.
research Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm
Phospholipid-coated nanoparticles penetrate hair follicles better than others, especially in pig ears.
research II Nanosciesce and Nanotecnology Biomedicals Symposium - Proceedings
Nanotechnology shows promise for better drug delivery and cancer treatment.
research Microneedle-Based Technologies for Long-Acting Transdermal Drug Delivery in Wearable Devices
Microneedles in wearables can deliver drugs over time but face challenges in manufacturing and safety.
research Aplicação da nanotecnologia no tratamento da alopecia
Nanotechnology can improve alopecia treatments but faces stability challenges.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Does anyone know the chemical formula for pelage pp405?
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.